Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial

Guo,Xi; Guo,Xi; Lou,Wenhui; Lou,Wenhui; Xu,Yaolin; Xu,Yaolin; Zhuang,Rongyuan; Zhuang,Rongyuan; Yao,Lie; Yao,Lie; Wu,Junwei; Wu,Junwei; Fu,Deliang; Fu,Deliang; Zhang,Jun; Zhang,Jun; Liu,Jing; Liu,Jing; Rong,Yefei; Rong,Yefei; Jin,Dayong; Jin,Dayong; Wu,Wenchuan; Wu,Wenchuan; Xu,Xuefeng; Xu,Xuefeng; Ji,Yuan; Ji,Yuan; Wu,Lili; Wu,Lili; Lv,Minzhi; Lv,Minzhi; Yao,Xiuzhong; Yao,Xiuzhong; Liu,Xiaowei; Liu,Xiaowei; Wang,Dansong; Wang,Dansong; Kuang,Tiantao; Kuang,Tiantao; Liu,Liang; Liu,Liang; Wang,Wenquan; Wang,Wenquan; Liu,Tianshu; Liu,Tianshu; Zhou,Yuhong; Zhou,Yuhong

doi:10.3892/ol.2024.14293

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial

Authors:
- Xi Guo
- Wenhui Lou
- Yaolin Xu
- Rongyuan Zhuang
- Lie Yao
- Junwei Wu
- Deliang Fu
- Jun Zhang
- Jing Liu
- Yefei Rong
- Dayong Jin
- Wenchuan Wu
- Xuefeng Xu
- Yuan Ji
- Lili Wu
- Minzhi Lv
- Xiuzhong Yao
- Xiaowei Liu
- Dansong Wang
- Tiantao Kuang
- Liang Liu
- Wenquan Wang
- Tianshu Liu
- Yuhong Zhou
View Affiliations

Affiliations: Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China, Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China, Department of Pathology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Radiotherapy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Biostatistics, Clinical Research Unit, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Radiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China, Department of Anti‑tumor Business, Shi Yao Group European Pharmaceutical Co., Ltd., Shijiazhuang, Hebei 050035, P.R. China
Published online on: February 19, 2024 https://doi.org/10.3892/ol.2024.14293
Article Number: 161
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with advanced pancreatic cancer (PC) need a cost‑effective treatment regimen. The present study was designed to compare the efficacy and safety of nab‑paclitaxel plus S‑1 (AS) and gemcitabine plus S‑1 (GS) regimens in patients with chemotherapy‑naïve advanced PC. In this open‑label, multicenter, randomized study named AvGmPC, eligible patients with chemotherapy‑naïve advanced PC were randomly assigned (1:1) to receive AS (125 mg/m² nab‑paclitaxel, days 1 and 8; 80‑120 mg S‑1, days 1‑14) or GS (1,000 mg/m² gemcitabine, days 1 and 8; 80‑120 mg S‑1, days 1‑14). The treatment was administered every 3 weeks until intolerable toxicity or disease progression occurred. The primary endpoint was progression‑free survival (PFS). Between December 2018 and March 2022, 101 of 106 randomized patients were treated and evaluated for analysis (AS, n=49; GS, n=52). As of the data cutoff, the median follow‑up time was 11.37 months [95% confidence interval (CI), 9.31‑13.24]. The median PFS was 7.16 months (95% CI, 5.19‑12.32) for patients treated with AS and 6.41 months (95% CI, 3.72‑8.84) for patients treated with GS (HR=0.78; 95% CI, 0.51‑1.21; P=0.264). The AS regimen showed a slightly improved overall survival (OS; 13.27 vs. 10.64 months) and a significantly improved ORR (44.90 vs. 15.38%; P=0.001) compared with the GS regimen. In the subgroup analyses, PFS and OS benefits were observed in patients treated with the AS regimen who had KRAS gene mutations and high C‑reactive protein (CRP) levels (≥5 mg/l). The most common grade ≥3 adverse events were neutropenia, anemia and alopecia in the two groups. Thrombocytopenia occurred more frequently in the GS group than in the AS group. While the study did not meet the primary endpoint, the response benefit observed for AS may be suggestive of meaningful clinical activity in this population. In particular, promising survival benefits were observed in the subsets of patients with KRAS gene mutations and high CRP levels, which is encouraging and warrants further investigation. This trial was retrospectively registered as ChiCTR1900024588 on July 18, 2019.

View Figures

View References

1	Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
3	Viale PH: The American Cancer Society's facts & figures: 2020 Edition. J Adv Pract Oncol. 11:135–136. 2020.PubMed/NCBI
4	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
5	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
6	Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL and Ducreux M: Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 57:10–22. 2016. View Article : Google Scholar : PubMed/NCBI
7	National Comprehensive Cancer Network (NCCN), . Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. (v. 1 2022). NCCN; Plymouth Meeting, PA: 2022
8	CSCO, . Guidelines of The Chinese Society of Clinical Oncology (CSCO) pancreatic cancer 2020. People's Medical Publishing House; Beijing: 2020
9	Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
10	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
11	Cui J, Jiao F, Li Q, Wang Z, Fu D, Liang J, Liang H, Xia T, Zhang T, Zhang Y, et al: Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. J National Cancer Center. 2:205–215. 2022. View Article : Google Scholar
12	Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, et al: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol. 32:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto Y, et al: Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 174:40–47. 2022. View Article : Google Scholar : PubMed/NCBI
14	Go SI, Lee SC, Bae WK, Zang DY, Lee HW, Jang JS, Ji JH, Kim JH, Park S, Sym SJ, et al: Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Eur J Cancer. 157:21–30. 2021. View Article : Google Scholar : PubMed/NCBI
15	Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
16	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
17	Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 61:615–621. 2008. View Article : Google Scholar : PubMed/NCBI
18	Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 94:1575–1579. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Yokosuka O, Tanaka K, Moriyasu F, et al: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol. 41:953–958. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhao Y and Yu X: Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 edition). J Clin Hepatol. 34:2109–2120. 2018.
21	Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, et al: Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 72:845–852. 2013. View Article : Google Scholar : PubMed/NCBI
22	Roy V, LaPlant BR, Gross GG, Bane CL and Palmieri FM; North Central Cancer Treatment Group, : Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 20:449–453. 2009. View Article : Google Scholar : PubMed/NCBI
23	Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
24	Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, et al: Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. J Thorac Oncol. 15:1351–1360. 2020. View Article : Google Scholar : PubMed/NCBI
25	Tahara J, Shimizu K, Otsuka N, Akao J, Takayama Y and Tokushige K: Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 82:245–250. 2018. View Article : Google Scholar : PubMed/NCBI
26	Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M and Kodera Y: S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 113:413–419. 2016. View Article : Google Scholar : PubMed/NCBI
27	Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY and Lou WH: Nab-Paclitaxel plus S-1 shows increased antitumor activity in patient-derived pancreatic cancer xenograft mouse models. Pancreas. 45:425–433. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhang W, Du C, Sun Y, Yang L, Cui C, Jiang Z, Wang C, Wang J and Zhou A: Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: A single-arm phase II trial. Cancer Chemother Pharmacol. 82:655–660. 2018. View Article : Google Scholar : PubMed/NCBI
29	Shi Y, Zhang S, Han Q, Li J, Yan H, Lv Y, Shi H, Liu R and Dai G: Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): A single arm, single center, phase II trial. Oncotarget. 8:92401–92410. 2017. View Article : Google Scholar : PubMed/NCBI
30	Dai YH, Yu XJ, Xu HT, Zhuang L, Zhang MS, Zou YM, Fu Q, Qiu H and Yuan XL: Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: Results of a multicenter, randomized, phase III trial (GAPSO study). Ther Adv Med Oncol. 14:175883592211180202022. View Article : Google Scholar : PubMed/NCBI
31	Morimoto M, Toba H, Aoyama M, Nakagawa M, Takechi H, Yoshida T and Tangoku A: Phase 1 Dose-Escalation study of triweekly Nab-Paclitaxel combined with S-1 for HER2-Negative metastatic breast cancer. Clin Breast Cancer. 20:448–453. 2020. View Article : Google Scholar : PubMed/NCBI
32	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
33	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
34	Freites-Martinez A, Santana N, Arias-Santiago S and Viera A: Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112:90–92. 2021.(English, Spanish). View Article : Google Scholar : PubMed/NCBI
35	Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L, Liu T, Xu B, Feng Y, Wang Y, et al: Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Jpn J Clin Oncol. 48:535–541. 2018. View Article : Google Scholar : PubMed/NCBI
36	Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L and Zhou J: Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: A randomized study. J Cancer Res Clin Oncol. 147:1529–1536. 2021. View Article : Google Scholar : PubMed/NCBI
37	Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K and Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 109:1561–1569. 2007. View Article : Google Scholar : PubMed/NCBI
38	Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, Sawaki A, Niwa Y, Tajika M, Kondo S, et al: Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 48:640–646. 2013. View Article : Google Scholar : PubMed/NCBI
39	Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, et al: Molecular characterization of KRAS Wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 28:2704–2714. 2022. View Article : Google Scholar : PubMed/NCBI
40	Li R, Ng TSC, Wang SJ, Prytyskach M, Rodell CB, Mikula H, Kohler RH, Garlin MA, Lauffenburger DA, Parangi S, et al: Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat Nanotechnol. 16:830–839. 2021. View Article : Google Scholar : PubMed/NCBI
41	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 68:171–178. 2005. View Article : Google Scholar : PubMed/NCBI
42	Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 26:2118–2123. 2008. View Article : Google Scholar : PubMed/NCBI
43	Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, et al: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 102:478–483. 2011. View Article : Google Scholar : PubMed/NCBI
44	Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:2203–2206. 1987.PubMed/NCBI